Clinical Trial: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282574) titled 'A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)' on Dec. 05.

Brief Summary: The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Study Start Date: Jan. 30, 2026

Study Type: INTERVENTIONAL

Condition: Progressive Multiple Sclerosis

Intervention: DRUG: RO7268489...